Ultragenyx Pharmaceutical Inc.RARE
Market cap
$3.2B
P/E ratio
| Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Product sales | - | - | - | - | 10 | 20 | 39 | 77 | 119 | 180 | 285 |
| Royalty revenue | - | - | - | - | - | - | 13 | 18 | 22 | 183 | 275 |
| Collaboration and license | - | - | - | - | 42 | 83 | 219 | 256 | 223 | 71 | - |
| Revenue | - | - | - | - | 51 | 104 | 271 | 351 | 363 | 434 | 560 |
| Cost of sales | - | - | - | - | - | 9 | 6 | 16 | 28 | 45 | 77 |
| Research and development | 46 | 115 | 183 | 232 | 294 | 357 | 412 | 497 | 706 | 648 | 698 |
| Selling, general and administrative | - | - | - | 100 | 128 | 162 | 183 | 220 | 278 | 310 | 322 |
| Total operating expenses | - | - | - | - | - | - | - | 733 | 1,012 | 1,003 | 1,096 |
| Loss from operations | -57 | -148 | -248 | -329 | -371 | -424 | -330 | -382 | -649 | -569 | -536 |
| Interest income | 1 | 2 | 4 | 4 | 10 | 13 | 7 | 2 | 11 | 27 | 37 |
| Equity Securities, FV-NI, Gain (Loss) | - | - | - | - | - | 13 | 170 | -42 | -19 | 0 | -1 |
| Non-cash interest expense on liabilities for sales of future royalties | - | - | - | - | - | 1 | 33 | 29 | 43 | 66 | 63 |
| Other expense | -4 | -0 | -2 | 7 | -6 | -1 | 1 | -2 | -2 | -0 | -4 |
| Loss before income taxes | - | - | -246 | -318 | -197 | -399 | -185 | -453 | -702 | -608 | -568 |
| (Provision for) benefit from income taxes | - | - | 0 | -16 | 1 | 3 | 1 | 1 | 6 | -2 | 2 |
| Net loss | -60 | -146 | -246 | -302 | -198 | -403 | -187 | -454 | -707 | -607 | -569 |
| Net loss per share, basic | - | - | - | - | - | - | - | - | -10.12 | -8.25 | -6.29 |
| Net loss per share, diluted | - | - | - | - | - | - | - | - | -10.12 | -8.25 | -6.29 |